• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

    7/6/26 8:30:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYFT alert in real time by email

    Inclusion in FTSE Russell's June 2026 semi-annual  reconstitution expands visibility among institutional investors and broadens eligibility for  index-tracking funds managing more than $12 trillion in benchmarked assets

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026.

    The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of the largest U.S.-domiciled public companies by market capitalization. Inclusion is determined, and since 2026 reconfirmed on a semi-annual basis in June and December, using market capitalization as of the rank date, with no application or fee required.

    "Being added to the Russell 3000E Index is a meaningful visibility milestone in MindWalk’s evolution as a public company. It places us in front of a broader set of institutional investors and index-tracking funds that had no mechanism to consider MindWalk before. We see this as one more signal that the market is starting to price the infrastructure layer beneath biological AI, not just the AI models running on top of it. "

    — Jennifer Bath, Ph.D., Chief Executive Officer and President, MindWalk Holdings Corp.

    Russell indexes are widely used as the basis for index funds and exchange-traded products. According to FTSE Russell, approximately USD 12.2 trillion in investor assets are benchmarked to, or invested in products based on, the Russell US Indexes.¹ Membership in the Russell 3000E Index means passive funds and other vehicles that track the index, or broader benchmarks built from it, are eligible to hold MindWalk shares as part of their standard rebalancing, without any action required by the Company.

    Russell index membership and associated indexes are calculated by FTSE Russell. For more information on the Russell indexes, methodology, and the full 2026 reconstitution results, visit ftserussell.com.

    About MindWalk Holdings Corp.

    MindWalk Holdings Corp. (NASDAQ:HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require, integrating AI, data, and advanced wet lab capabilities into one connected discovery ecosystem. At its core is HYFT® Technology, a proprietary, function-aware representation of biology. Its HYFT fingerprints span sequence and structural biology and, refined over 20 years of curation, form a continuously evolving biological representation of 660 million patterns and 25 billion relationships. This enriched biological representation is the architecture behind ReefIQ™, the biological data substrate that provides context for life sciences, enriching data at ingestion and growing more valuable with each program run on it, and LensAI™, the reasoning and application layer for target discovery, candidate diligence, portfolio decision support, and the agentic AI workflows pharma is racing to deploy. By design, value compounds in this HYFT representation layer, not in any individual AI model that runs on top of it.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks that MindWalk's inclusion in the Russell 3000E Index does not guarantee, and should not be interpreted as an assurance of, any level of trading volume, liquidity, share price performance, or investment return; the possibility that FTSE Russell may remove MindWalk from the Russell 3000E Index or any related index at a future reconstitution based on market capitalization or other index-eligibility criteria outside the Company's control; the fact that index inclusion does not constitute an endorsement of MindWalk by FTSE Russell or any index-tracking fund; general risks related to capital markets conditions, share price volatility, and investor sentiment; and the other risks and uncertainties affecting MindWalk's business, including those related to the commercial adoption of its HYFT® Technology, ReefIQ™, and LensAI™ infrastructure. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. Nothing in this press release constitutes investment advice. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

    Trademarks

    HYFT® is a registered trademark of MindWalk Holdings Corp. LensAI™, ReefIQ™, HYFT Base™, HYFT Matrix™, HYFT Prime™, and B cell Llama™ are trademarks of MindWalk Holdings Corp. or its subsidiaries; ReefIQ™ registration is pending. All other trademarks are the property of their respective owners.

    References

    [1] FTSE Russell / LSEG, Russell Reconstitution investor materials, 2026 (approximately USD 12.2 trillion in investor assets benchmarked to or invested in products based on the Russell US Indexes, as of June 30, 2025). Figure is a third-party estimate presented for context only.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260706301646/en/

    Investor Contact

    Louie Toma, CPA, CFA

    Managing Director, CoreIR

    investors@mindwalkAI.com

    Get the next $HYFT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYFT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

    MindWalk to host an earnings conference call and webcast MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it will report financial results for the fourth quarter and full fiscal year 2026 and host a conference call on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details Event Date and Time: Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time The conference call will be webcast live and available for replay via a link provided

    7/13/26 9:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

    Inclusion in FTSE Russell's June 2026 semi-annual  reconstitution expands visibility among institutional investors and broadens eligibility for  index-tracking funds managing more than $12 trillion in benchmarked assets MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of the larges

    7/6/26 8:30:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    SEC Filings

    View All

    SEC Form F-3 filed by MindWalk Holdings Corp.

    F-3 - MindWalk Holdings Corp. (0001715925) (Filer)

    7/13/26 4:01:57 PM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    7/13/26 12:33:43 PM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    7/6/26 10:10:02 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

    6/12/26 9:00:00 AM ET
    $ABSI
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM. The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk's HYFT®-powered LensAi™ platform is unlocking new op

    11/13/25 9:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    Financials

    Live finance-specific insights

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

    MindWalk to host an earnings conference call and webcast MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it will report financial results for the fourth quarter and full fiscal year 2026 and host a conference call on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details Event Date and Time: Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time The conference call will be webcast live and available for replay via a link provided

    7/13/26 9:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

    Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform MindWalk Holdings Corp. (NASDAQ:HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year revenue growth. US revenue doubled year over year to $2.6 million

    3/12/26 8:31:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care